Agenus

AGEN NASDAQ
2.960
+0.010
+0.34%
Closed 16:09 08/22 EDT
Open
2.970
Prev Close
2.950
High
3.000
Low
2.870
Volume
1.55M
Avg Vol (3M)
981.90K
52 Week High
3.880
52 Week Low
1.540
% Turnover
1.13%
Market Cap
406.45M
1D
5D
1M
3M
1Y
5Y

Company Profile

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
MORE >

Recently

Name
Price
%Change